Education
About Us
Working with TipRanks
Follow Us
Vir Biotechnology (VIR)
NASDAQ:VIR
VIR Stock Chart & Stats
$6.19
$5.76(73.00%)
At close: 4:00 PM EST
$6.19
$5.76(73.00%)
Day’s Range― - ―
52-Week Range$4.16 - $14.45
Previous CloseN/A
Volume25.73M
Average Volume (3M)1.41M
Market Cap
$830.72M
Enterprise Value$105.77M
Total Cash (Recent Filing)$686.97M
Total Debt (Recent Filing)$93.41M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Nov 05, 2025EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding138,916,430
10 Day Avg. Volume1,481,726
30 Day Avg. Volume1,413,990
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)0.87
Price to Sales (P/S)13.48
P/FCF Ratio-2.20
Enterprise Value/Market Cap0.13
Enterprise Value/Revenue6.35
Enterprise Value/Gross Profit6.64
Enterprise Value/Ebitda-0.18
Forecast
1Y Price Target
$16.29Price Target Upside163.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Market PotentialVir's hepatitis delta virus (HDV) franchise is in late-stage development, with potential best-in-class agents positioned in a concentrated market lacking U.S.-approved therapies.
Oncology Pipeline ProgressVir’s oncology pipeline is advancing significantly with multiple active clinical programs supported by proprietary dual-masking technology.
Regulatory AdvancementsThe ECLIPSE program for chronic hepatitis delta is enrolling across all three registrational studies, marking a critical advancement for Vir’s lead infectious disease franchise. The program has received Breakthrough Therapy and Fast Track designations in the U.S., and PRIME and Orphan Drug designations in the EU, which may streamline regulatory engagement.
Bears Say
Competitive RisksVIR-5500 may fail to produce competitive data.
Stock PerformanceThe stock has traded down 40% year-to-date, attributed to a lack of catalyst flow and concerns on cash burn.
Undervaluation ConcernsMinimal value seems to be attributed to T-cell engager oncology programs despite initial proof-of-concept data, suggesting an undervaluation.
Vir Biotechnology News
VIR FAQ
What was Vir Biotechnology’s price range in the past 12 months?
Vir Biotechnology lowest stock price was $4.16 and its highest was $14.45 in the past 12 months.
What is Vir Biotechnology’s market cap?
Vir Biotechnology’s market cap is $830.72M.
When is Vir Biotechnology’s upcoming earnings report date?
Vir Biotechnology’s upcoming earnings report date is Nov 05, 2025 which is in 7 days.
How were Vir Biotechnology’s earnings last quarter?
Vir Biotechnology released its earnings results on Aug 06, 2025. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.723 by -$0.077.
Is Vir Biotechnology overvalued?
According to Wall Street analysts Vir Biotechnology’s price is currently Undervalued.
Does Vir Biotechnology pay dividends?
Vir Biotechnology does not currently pay dividends.
What is Vir Biotechnology’s EPS estimate?
Vir Biotechnology’s EPS estimate is -0.84.
How many shares outstanding does Vir Biotechnology have?
Vir Biotechnology has 138,916,430 shares outstanding.
What happened to Vir Biotechnology’s price movement after its last earnings report?
Vir Biotechnology reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.723. Following the earnings report the stock price went down -14.37%.
Which hedge fund is a major shareholder of Vir Biotechnology?
Currently, no hedge funds are holding shares in VIR
Vir Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.29 (163.17% Upside)
$16.29 (163.17% Upside)
Blogger Sentiment
Bullish
VIR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 363.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.24%
12-Months-Change
Fundamentals
Return on Equity
-46.22%
Trailing 12-Months
Asset Growth
-28.57%
Trailing 12-Months
Company Description
Vir Biotechnology
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
VIR Company Deck
VIR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights Vir Biotechnology's significant progress in their ECLIPSE program and T cell engager portfolio, alongside a strong financial position and reduced operating expenses. However, the company continues to face challenges with net losses and estimating the HDV patient population.View all VIR earnings summariesVIR Stock 12 Month Forecast
Average Price Target
$16.29
▲(163.17% Upside)
Technical Analysis
Ownership Overview
16.13% Insiders
15.45% Mutual Funds
0.03% Other Institutional Investors
48.63% Public Companies and
Individual Investors